Skip to main
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology Inc's robust growth projections indicate anticipated launch sales of approximately $2.6 billion by 2034, driven by the premium pricing of its lead candidate, cretostimogene grenadenorepvec (Creto), which positions it favorably within the bladder cancer treatment market. The company's focus on addressing an unmet need for effective therapies that reduce disease recurrence, coupled with Creto's differentiated efficacy demonstrated in clinical studies, enhances its potential market adoption among healthcare professionals and patients. Additionally, strategic plans for Creto to expand into different patient populations signal significant revenue opportunities, projected to reach about $1 billion in peak revenues for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Bears say

CG Oncology Inc faces significant risks regarding the commercial viability of its lead therapeutic candidate, cretostimogene grenadenorepvec, due to historical precedents in oncology where products failed in the market despite high pricing and insufficient differentiating advantages. Concerns regarding potential negative trial outcomes, slower-than-expected enrollment, and adverse regulatory decisions pose substantial threats to the timeline and scope of commercial launch, which could ultimately delay revenues. Additionally, vulnerabilities related to intellectual property protection and reimbursement challenges from payers heighten the uncertainty surrounding the company's financial future and market positioning.

CGON has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 11 analysts, CGON has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.